Cutaneous leukocytoclastic vasculitis associated with erlotinib treatment: A case report and review of the literature

被引:28
作者
Fekete, Gyula Laszlo [1 ]
Fekete, Laszlo [2 ]
机构
[1] Univ Med & Pharm, Dermatol Clin, 12 Gheorghe Doja St, Targu Mures 540530, Romania
[2] CMI Dermamed, Targu Mures 540530, Romania
关键词
EGFR inhibitors; lung adenocarcinoma; erlotinib; cutaneous side effects; vasculitis; MARKER;
D O I
10.3892/etm.2018.6988
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Erlotinib is a targeted anticancer therapy used for treating epidermal growth factor receptor (EGFR) mutation positive lung cancer in advanced stage as well as for other malignancies. The most common cutaneous side effect of erlotinib, are well documented; however the number of reports regarding cutaneous leukocytoclastic vasculitis (CLCV) are limited. We report a case, a 58-year-old, 60 kg weight, non-smoking woman suffering of lung adenocarcinoma and brain metastases treated with erlotinib monotherapy with 150 mg/day dose, who presents cutaneous leukocytoclastic vasculitis after 8 months of initiating the treatment. The administration of the drug was discontinued and oral prednisolone treatment was introduced at 1 mg/kg body weight dose for two weeks, decreasing the dose with 5 mg, at every 3 days. The treatment was combined with topical potent steroid and antibiotic therapy used once, daily. The lesions cleared within 7 weeks without recurrence. The treatment with erlotinib was restarted after 14 days with a lower dose of 100 mg/day. The skin lesions have not occurred anymore. Unfortunately the evolution was unfavorable, our patient died 3 months after the vasculitis healing, due to the complications of new metastases that occurred. This may indicate the inefficiency of erlotinib. The late onset of 240 days of the vasculitis and the presumed inefficiency of the drug lead to the speculation that the appearance of cutaneous vasculitis could be a worsening clinical marker of the tumor response. This limited number of cases precludes any meaningful interpretation of data about the erlotinib induced cutaneous vasculitis. Further investigations are needed to assess cutaneous vasculitis.
引用
收藏
页码:1128 / 1131
页数:4
相关论文
共 17 条
[1]   Leukocytociastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib [J].
Boeck, S. ;
Wollenberg, A. ;
Heinemann, V. .
ANNALS OF ONCOLOGY, 2007, 18 (09) :1582-1583
[2]   Cutaneous leukocytoclastic vasculitis due to erlotinib: just an adverse event or also a putative marker of drug efficacy? [J].
Brandi, Giovanni ;
Venturi, Michela ;
Dika, Emi ;
Maibach, Howard ;
Patrizi, Annalisa ;
Biasco, Guido .
CUTANEOUS AND OCULAR TOXICOLOGY, 2013, 32 (04) :336-338
[3]   Drug-induced Rowell syndrome, a rare and difficult to manage disease: A case report [J].
Branisteanu, Daciana Elena ;
Ianosi, Simona Laura ;
Dimitriu, Andreea ;
Stoleriu, Gabriela ;
Oanta, Alexandru ;
Branisteanu, Daniel Constantin .
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2018, 15 (01) :785-788
[4]   Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors [J].
Faye, Emmanuelle ;
Bondon-Guitton, Emmanuelle ;
Olivier-Abbal, Pascale ;
Montastruc, Jean-Louis .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (10) :1819-1826
[5]  
Gheorghe I, 2017, ROM BIOTECH LETT, V22, P12321
[6]  
Hakeem AH, 2015, JMSCR, V3, P3890
[7]   A spectrum of cutaneous toxicities from erlotinib may be a robust clinical marker for non-small-cell lung therapy: a case report and literature review [J].
Jin, Feng ;
Zhu, Hui ;
Kong, Li ;
Yu, Jinming .
ONCOTARGETS AND THERAPY, 2015, 8 :943-946
[8]   Leukocytoclastic Vasculitis after Long-Term Treatment with Sunitinib: A Case Report [J].
Karadimou, Alexandra ;
Migou, Magdalini ;
Economidi, Afroditi ;
Stratigos, Alexandros ;
Kittas, Christos ;
Dimopoulos, Meletios A. ;
Bamias, Aristotle .
CASE REPORTS IN ONCOLOGY, 2011, 4 (02) :385-391
[9]   Skin Rash could Predict the Response to EGFR Tyrosine Kinase Inhibitor and the Prognosis for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis [J].
Liu, Hong-bing ;
Wu, Ying ;
Lv, Tang-feng ;
Yao, Yan-wen ;
Xiao, Yong-ying ;
Yuan, Dong-mei ;
Song, Yong .
PLOS ONE, 2013, 8 (01)
[10]   A case of necrotizing vasculitis with panniculitis, during sorafenib treatment for hepatocellular carcinoma, appeared in disease progression [J].
Panebianco, Michele ;
Ragazzi, Moira ;
Asensio, Nuria Maria ;
Pagano, Maria ;
Gnoni, Roberta ;
Boni, Corrado .
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2014, 5 (06) :E121-E124